Objective To summarize the clinical characteristics, treatment outcomes, and prognostic factors of children with non-metastatic Ewing's sarcoma (ES). Methods A retrospective analysis was conducted on the clinical data of 41 children with non-metastatic ES diagnosed and treated at the Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine from January 2010 to December 2018. All patients underwent chemotherapy based on the RMS-2009 protocol of the center, and local treatment such as surgery and/or radiotherapy was performed according to risk grouping. The Kaplan-Meier method was used to calculate the overall survival (OS) and event-free survival (EFS) rates. Univariate prognostic analysis was performed using the log-rank test, and multivariate analysis was conducted with Cox regression. Results Of the 41 children, 21 were male and 20 were female. The median age at diagnosis was 7.7 years (range: 1.2-14.6 years). The median follow-up time for patients with event-free survival was 68.1 months (range: 8.1-151.7 months). As of the last follow-up, 33 patients were in complete remission, and the overall 5-year EFS and OS rates were (78±6)% and (82±6)%, respectively. Univariate analysis by the log-rank test showed that a tumor diameter ≥8 cm, time from diagnosis to start of local treatment ≥16 weeks, and incomplete surgical resection were associated with poor prognosis (P<0.05). Multivariate Cox regression analysis indicated that incomplete surgical resection (HR=8.381, 95%CI: 1.681-41.801, P=0.010) was an independent risk factor for poor prognosis in children with ES. Secondary tumors occurred in 2 cases. Conclusions A comprehensive treatment strategy incorporating chemotherapy, surgery, and radiotherapy can improve the prognosis of children with ES. Poor prognosis is associated with an initial tumor diameter ≥8 cm, while complete surgical resection and early initiation of local treatment can improve outcomes.
YUAN Qing, HAN Ya-Li, PAN Ci, TANG Jing-Yan, GAO Yi-Jin.
Analysis of 41 cases of non-metastatic Ewing's sarcoma in children[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(4): 365-370 https://doi.org/10.7499/j.issn.1008-8830.2309077
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma[J]. Pediatr Blood Cancer, 2021, 68 (Suppl 2): e28355. PMID: 33818887. DOI: 10.1002/pbc.28355. 2 Gargallo P, Yá?ez Y, Juan A, et al. Review: Ewing sarcoma predisposition[J]. Pathol Oncol Res, 2020, 26(4): 2057-2066. PMID: 31656020. DOI: 10.1007/s12253-019-00765-3. 3 Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma[J]. Nat Rev Dis Primers, 2018, 4(1): 5. PMID: 29977059. DOI: 10.1038/s41572-018-0003-x. 4 Riggi N, Suvà ML, Stamenkovic I. Ewing's sarcoma[J]. Engl J Med, 2021, 384(2): 154-164. PMID: 33497548. DOI: 10.1056/NEJMra2028910. 5 Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2012, 30(33): 4148-4154. PMID: 23091096. PMCID: PMC3494838. DOI: 10.1200/JCO.2011.41.5703. 6 Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1): 207-214. PMID: 7459811. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. 7 Chin M, Yokoyama R, Sumi M, et al. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: results of the Japan Ewing Sarcoma Study 04[J]. Pediatr Blood Cancer, 2020, 67(5): e28194. PMID: 32077253. DOI: 10.1002/pbc.28194. 8 Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study[J]. J Clin Oncol, 2009, 27(15): 2536-2541. PMID: 19349548. PMCID: PMC2684856. DOI: 10.1200/JCO.2008.19.1478. 9 Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone[J]. N Engl J Med, 2003, 348(8): 694-701. PMID: 12594313. DOI: 10.1056/NEJMoa020890. 10 Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial[J]. Pediatr Blood Cancer, 2006, 47(1): 22-29. PMID: 16572419. DOI: 10.1002/pbc.20820. 11 Whelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008[J]. J Clin Oncol, 2018, 36(31): JCO2018782516. PMID: 30188789. PMCID: PMC6209090. DOI: 10.1200/JCO.2018.78.2516. 12 董玉双, 谈珍, 张勤, 等. 儿童尤文肉瘤家族肿瘤50例临床病理特点及预后因素分析[J]. 临床儿科杂志, 2020, 38(7): 530-535. DOI: 10.3969/j.issn.1000-3606.2020.07.012. 13 Kapoor G, Jain S. Choice of local therapy in children with Ewing sarcoma[J]. Indian Pediatr, 2020, 57(6): 503-504. PMID: 32562393. 14 Lin TA, Ludmir EB, Liao KP, et al. Timing of local therapy affects survival in Ewing sarcoma[J]. Int J Radiat Oncol Biol Phys, 2019, 104(1): 127-136. PMID: 30593906. DOI: 10.1016/j.ijrobp.2018.12.032. 15 Salah S, Halalsheh H, Abuhijla F, et al. The impact of local control timing in Ewing sarcoma[J]. Rep Pract Oncol Radiother, 2020, 25(2): 255-259. PMID: 32140082. PMCID: PMC7049602. DOI: 10.1016/j.rpor.2020.02.001. 16 Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 168-177. PMID: 12504050. DOI: 10.1016/s0360-3016(02)03797-5. 17 Whelan J, Hackshaw A, McTiernan A, et al. Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92[J]. Clin Sarcoma Res, 2018, 8: 6. PMID: 29610659. PMCID: PMC5877389. DOI: 10.1186/s13569-018-0093-y. 18 Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children's Oncology Group[J]. J Clin Oncol, 2006, 24(24): 3838-3843. PMID: 16921035. DOI: 10.1200/JCO.2006.05.9188. 19 Z?llner SK, Amatruda JF, Bauer S, et al. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives[J]. J Clin Med, 2021, 10(8): 1685. PMID: 33919988. PMCID: PMC8071040. DOI: 10.3390/jcm10081685. 20 Abbott D, O'Brien S, Farnham JM, et al. Increased risk for other cancers in individuals with Ewing sarcoma and their relatives[J]. Cancer Med, 2019, 8(18): 7924-7930. PMID: 31670911. PMCID: PMC6912049. DOI: 10.1002/cam4.2575. 21 Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: a systematic review[J]. Pediatr Blood Cancer, 2019, 66(11): e27938. PMID: 31347793. DOI: 10.1002/pbc.27938. 22 Friedman DN, Chastain K, Chou JF, et al. Morbidity and mortality after treatment of Ewing sarcoma: a single-institution experience[J]. Pediatr Blood Cancer, 2017, 64(11): e26562. PMID: 28417551. DOI: 10.1002/pbc.26562. 23 Nguyen F, Rubino C, Guerin S, et al. Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3): 908-915. PMID: 18262102. DOI: 10.1016/j.ijrobp.2007.10.034. 24 Sanford NN, Miao R, Wang H, et al. Characteristics and predictors for secondary leukemia and myelodysplastic syndrome in Ewing and osteosarcoma survivors[J]. Int J Radiat Oncol Biol Phys, 2019, 103(1): 52-61. PMID: 30165126. DOI: 10.1016/j.ijrobp.2018.08.037. 25 Hong KT, Choi JY, Hong CR, et al. Therapy-related acute myeloid leukemia after the treatment of primary solid cancer in children: a single-center experience[J]. J Pediatr Hematol Oncol, 2018, 40(1): e23-e28. PMID: 29200163. DOI: 10.1097/MPH.0000000000001019. 26 Sultan I, Rihani R, Hazin R, et al. Second malignancies in patients with Ewing sarcoma family of tumors: a population-based study[J]. Acta Oncol, 2010, 49(2): 237-244. PMID: 20100158. DOI: 10.3109/02841860903253538. 27 Vyas C, Jain S, Kapoor G. Therapy related AML/MDS following treatment for childhood cancer: experience from a tertiary care centre in north India[J]. Indian J Hematol Blood Transfus, 2018, 34(1): 78-82. PMID: 29398803. PMCID: PMC5786633. DOI: 10.1007/s12288-017-0840-x. 28 Zhang J, Nichols KE, Downing JR. Germline mutations in predisposition genes in pediatric cancer[J]. N Engl J Med, 2016, 374(14): 1391. PMID: 27050224. DOI: 10.1056/NEJMc1600338. 29 Renzi S, Anderson ND, Light N, et al. Ewing-like sarcoma: an emerging family of round cell sarcomas[J]. J Cell Physiol, 2019, 234(6): 7999-8007. PMID: 30257034. DOI: 10.1002/jcp.27558. 30 Sbaraglia M, Righi A, Gambarotti M, et al. Ewing sarcoma and Ewing-like tumors[J]. Virchows Arch, 2020, 476(1): 109-119. PMID: 31802230. DOI: 10.1007/s00428-019-02720-8.
PDF(560 KB)
